SDC1 and plasma cell myeloma: Given the importance of syndecan-1 HSPG in several cancer types, including breast, colon, lung, and myeloma, the development of new HS-binding antibodies and antibody derivatives is important for therapy and for understanding the functional roles of HS sulfation in syndecan-1.